Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2017

Open Access 01-12-2017 | Original investigation

Remote ischemic preconditioning differentially attenuates post-ischemic cardiac arrhythmia in streptozotocin-induced diabetic versus nondiabetic rats

Authors: Zhaoyang Hu, Mou Chen, Ping Zhang, Jin Liu, Geoffrey W. Abbott

Published in: Cardiovascular Diabetology | Issue 1/2017

Login to get access

Abstract

Background

Sudden cardiac death (SCD), a leading cause of global mortality, most commonly arises from a substrate of cardiac ischemia, but requires an additional trigger. Diabetes mellitus (DM) predisposes to SCD even after adjusting for other DM-linked cardiovascular pathology such as coronary artery disease. We previously showed that remote liver ischemia preconditioning (RLIPC) is highly protective against cardiac ischemia reperfusion injury (IRI) linked ventricular arrhythmias and myocardial infarction, via induction of the cardioprotective RISK pathway, and specifically, inhibitory phosphorylation of GSK-3β (Ser 9).

Methods

We evaluated the impact of acute streptozotocin-induced DM on coronary artery ligation IRI-linked ventricular arrhythmogenesis and RLIPC therapy in rats.

Results

Post-IRI arrhythmia induction was similar in nondiabetic and DM rats, but, unexpectedly, DM rats exhibited lower incidence of SCD during reperfusion (41 vs. 100%), suggesting uncontrolled hyperglycemia does not acutely predispose to SCD. RLIPC was highly effective in both nondiabetic and DM rats at reducing incidence and duration of, and increasing latency to, all classes of ventricular tachyarrhythmias. In contrast, atrioventricular block (AVB) was highly responsive to RLIPC in nondiabetic rats (incidence reduced from 72 to 18%) but unresponsive in DM rats. RISK pathway induction was similar in nondiabetic and DM rats, thus not explaining the DM-specific resistance of AVB to therapy.

Conclusions

Our findings uncover important acute DM-specific differences in responsiveness to remote preconditioning for ventricular tachyarrhythmias versus AVB, which may have clinical significance given that AVB is a malignant arrhythmia twofold more common in human diabetics than nondiabetics, and correlated to plasma glucose levels >10 mmol/L.
Literature
1.
Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, Estes M, Jouven X, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010;122(22):2335–48.CrossRefPubMedPubMedCentral
2.
3.
Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. Lancet. 1999;354(9194):1968–9.CrossRefPubMed
4.
Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K, Jui J. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51(3):213–28.CrossRefPubMedPubMedCentral
5.
Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord. 2010;11(1):53–9.CrossRefPubMedPubMedCentral
6.
Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48(5):937–42.CrossRefPubMed
7.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.CrossRefPubMed
8.
Thorn LM, Forsblom C, Waden J, Saraheimo M, Tolonen N, Hietala K, Groop PH, Finnish Diabetic Nephropathy Study G. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009;32(5):950–2.CrossRefPubMedPubMedCentral
9.
Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O, Junttila MJ, Knekt P, Huikuri HV. Diabetes, glucose tolerance, and the risk of sudden cardiac death. BMC Cardiovasc Disord. 2016;16:51.CrossRefPubMedPubMedCentral
10.
Reinier K, Nichols GA, Huertas-Vazquez A, Uy-Evanado A, Teodorescu C, Stecker EC, Gunson K, Jui J, Chugh SS. Distinctive clinical profile of blacks versus whites presenting with sudden cardiac arrest. Circulation. 2015;132(5):380–7.CrossRefPubMedPubMedCentral
11.
Axelsen LN, Calloe K, Braunstein TH, Riemann M, Hofgaard JP, Liang B, Jensen CF, Olsen KB, Bartels ED, Baandrup U, et al. Diet-induced pre-diabetes slows cardiac conductance and promotes arrhythmogenesis. Cardiovasc Diabetol. 2015;14:87.CrossRefPubMedPubMedCentral
12.
Hu Z, Hu S, Yang S, Chen M, Zhang P, Liu J, Abbott GW. Remote liver ischemic preconditioning protects against sudden cardiac death via an ERK/GSK-3β-dependent mechanism. PLoS ONE. 2016;11(10):e0165123.CrossRefPubMedPubMedCentral
13.
Yang S, Abbott GW, Gao WD, Liu J, Luo C, Hu Z. Involvement of glycogen synthase kinase-3β in liver ischemic conditioning induced cardioprotection against myocardial ischemia and reperfusion injury in rats. J Appl Physiol (1985). 2017:jap.00862 02016.
14.
15.
Hu Z, Crump SM, Zhang P, Abbott GW. Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res. 2016;110(2):227–37.CrossRefPubMed
16.
Hu Z, Kant R, Anand M, King EC, Krogh-Madsen T, Christini DJ, Abbott GW. Kcne2 deletion creates a multisystem syndrome predisposing to sudden cardiac death. Circ Cardiovasc Genet. 2014;7(1):33–42.CrossRefPubMedPubMedCentral
17.
Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. In: Mayo clinic proceedings, vol. 84, no. 3. 2009. p. 289–97.
18.
Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31(4):714–9.CrossRefPubMed
19.
20.
Epstein FH. Hyperglycemia. A risk factor in coronary heart disease. Circulation. 1967;36(4):609–19.CrossRefPubMed
21.
Epstein FH. Hyperglycemia, diabetes and coronary heart disease. G Ital Cardiol. 1974;4(2):223–9.PubMed
22.
Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther. 2011;16(3–4):255–9.CrossRefPubMed
23.
Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J, Holtby HM, Cox PN, Smallhorn JF, Van Arsdell GS, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol. 2006;47(11):2277–82.CrossRefPubMed
24.
Slagsvold KH, Rognmo O, Hoydal M, Wisloff U, Wahba A. Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. Circ Res. 2014;114(5):851–9.CrossRefPubMed
25.
Baranyai T, Nagy CT, Koncsos G, Onodi Z, Karolyi-Szabo M, Makkos A, Varga ZV, Ferdinandy P, Giricz Z. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. 2015;14:151.CrossRefPubMedPubMedCentral
26.
Han Z, Cao J, Song D, Tian L, Chen K, Wang Y, Gao L, Yin Z, Fan Y, Wang C. Autophagy is involved in the cardioprotection effect of remote limb ischemic postconditioning on myocardial ischemia/reperfusion injury in normal mice, but not diabetic mice. PLoS ONE. 2014;9(1):e86838.CrossRefPubMedPubMedCentral
27.
Movahed MR. Diabetes as a risk factor for cardiac conduction defects: a review. Diabetes Obes Metab. 2007;9(3):276–81.CrossRefPubMed
28.
Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. Chest. 2005;128(4):2611–4.CrossRefPubMed
29.
Podlaha R, Falk A. The prevalence of diabetes mellitus and other risk factors of atherosclerosis in bradycardia requiring pacemaker treatment. Horm Metab Res Suppl. 1992;26:84–7.PubMed
30.
Panja M, Dutta AL, Kar AK, Panja S, Chhetri MK. Cardiac changes implicated in chronic heart block. J Assoc Physicians India. 1991;39(9):698–701.PubMed
31.
Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol. 2011;51(4):607–13.CrossRefPubMed
32.
Miura T, Miki T. GSK-3β, a therapeutic target for cardiomyocyte protection. Circ J. 2009;73(7):1184–92.CrossRefPubMed
33.
Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90(4):1507–46.CrossRefPubMed
34.
Huang B, Wang X, Yang Y, Zhu J, Liang Y, Tan H, Yu L, Gao X, Zhang H, Wang J. Association of admission glycaemia with high grade atrioventricular block in ST-segment elevation myocardial infarction undergoing reperfusion therapy: an observational study. Medicine. 2015;94(28):e1167.CrossRefPubMedPubMedCentral
35.
Hung KC, Lin FC, Chern MS, Chang HJ, Hsieh IC, Wu D. Mechanisms and clinical significance of transient atrioventricular block during dobutamine stress echocardiography. J Am Coll Cardiol. 1999;34(4):998–1004.CrossRefPubMed
36.
Sykora M, Diedler J, Poli S, Rizos T, Kellert L, Turcani P, Steiner T. Association of non-diabetic hyperglycemia with autonomic shift in acute ischaemic stroke. Eur J Neurol. 2012;19(1):84–90.CrossRefPubMed
37.
De Angelis K, Senador DD, Mostarda C, Irigoyen MC, Morris M. Sympathetic overactivity precedes metabolic dysfunction in a fructose model of glucose intolerance in mice. Am J Physiol Regul Integr Comp Physiol. 2012;302(8):R950–7.CrossRefPubMedPubMedCentral
38.
Lee SM, Nguyen D, Anand M, Kant R, Kohncke C, Lisewski U, Roepke TK, Hu Z, Abbott GW. Kcne2 deletion causes early-onset nonalcoholic fatty liver disease via iron deficiency anemia. Sci Rep. 2016;6:23118.CrossRefPubMedPubMedCentral
39.
Lee SM, Nguyen D, Hu Z, Abbott GW. Kcne2 deletion promotes atherosclerosis and diet-dependent sudden death. J Mol Cell Cardiol. 2015;87:148–51.CrossRefPubMed
40.
McCrossan ZA, Roepke TK, Lewis A, Panaghie G, Abbott GW. Regulation of the Kv2.1 potassium channel by MinK and MiRP1. J Membr Biol. 2009;228(1):1–14.CrossRefPubMedPubMedCentral
41.
Roepke TK, Anantharam A, Kirchhoff P, Busque SM, Young JB, Geibel JP, Lerner DJ, Abbott GW. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion. J Biol Chem. 2006;281(33):23740–7.CrossRefPubMed
42.
Roepke TK, King EC, Reyna-Neyra A, Paroder M, Purtell K, Koba W, Fine E, Lerner DJ, Carrasco N, Abbott GW. Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis. Nat Med. 2009;15(10):1186–94.CrossRefPubMedPubMedCentral
43.
Sabater-Lleal M, Malarstig A, Folkersen L, Soler Artigas M, Baldassarre D, Kavousi M, Almgren P, Veglia F, Brusselle G, Hofman A, et al. Common genetic determinants of lung function, subclinical atherosclerosis and risk of coronary artery disease. PLoS ONE. 2014;9(8):e104082.CrossRefPubMedPubMedCentral
44.
Wakil SM, Ram R, Muiya NP, Mehta M, Andres E, Mazhar N, Baz B, Hagos S, Alshahid M, Meyer BF, et al. A genome-wide association study reveals susceptibility loci for myocardial infarction/coronary artery disease in Saudi Arabs. Atherosclerosis. 2016;245:62–70.CrossRefPubMed
45.
46.
Giblett JP, Axell RG, White PA, Clarke SJ, McCormick L, Read PA, Reinhold J, Brown AJ, O’Sullivan M, West NE, et al. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol. 2016;15:99.CrossRefPubMedPubMedCentral
Metadata
Title
Remote ischemic preconditioning differentially attenuates post-ischemic cardiac arrhythmia in streptozotocin-induced diabetic versus nondiabetic rats
Authors
Zhaoyang Hu
Mou Chen
Ping Zhang
Jin Liu
Geoffrey W. Abbott
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0537-3

Other articles of this Issue 1/2017

Cardiovascular Diabetology 1/2017 Go to the issue

Original investigation

Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure

Review

Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection

Original article

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

Original investigation

Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post-hoc analysis of HI-5 data

Correction

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Original investigation

Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits